Skip to content

Barij Jaundice and Neonatal Jaundice

studying the effect of Barij Jaundice oral drops containing extracts of Cotoneaster frigidus and Manna of hedysarum on the recovery of neonatal jaundice

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220512054829N8
Enrollment
70
Registered
2025-12-19
Start date
2025-12-22
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Baby jaundice. Neonatal jaundice, unspecified

Interventions

Intervention 1: Recipients of Barij Jaundice oral drops manufactured by Barij Essence Pharmaceutical Company along with phototherapy. Intervention 2: Control group: Recipients of placebo drops plus ph

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Days to 10 Days

Inclusion criteria

Inclusion criteria: The baby is born between 37 and 42 weeks of pregnancy. Be healthy. Be breastfed. The baby's weight should be between 2.5 and 4 kilograms. They have turned yellow after 36 hours from birth to day 14. The baby has an indication for phototherapy.

Exclusion criteria

Exclusion criteria: Presence of any malformations and comorbidities such as sepsis Maternal and fetal blood incompatibility Presence of direct jaundice

Design outcomes

Primary

MeasureTime frame
Total Bilirubin. Timepoint: Study start times: 24, 48, 72, 96 hours after starting treatment. Method of measurement: Blood test.;Need for hospitalization. Timepoint: During one week of treatment. Method of measurement: Clinical examination of the patient and blood tests.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Akbari

Kashan University of Medical Sciences

akbari1350_h@yahoo.com+98 31 5510 3523

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026